Osteoprotegerin concentration is associated with the presence and severity of peripheral arterial disease in type 2 diabetes mellitus.

Background: Osteoprotegerin plays a role in the development of several bone diseases. In addition, osteoprotegerin may contribute to the development of vascular disease. Little is known about the association between serum osteoprotegerin levels and the presence or severity of peripheral arterial disease (PAD). The aim of this study was to examine the association between serum osteoprotegerin levels and both the presence as well as the severity of lower extremity arterial disease in patients with type 2 diabetes (T2DM). Patients and methods: The study included 165 consecutive patients with T2DM (57 % males, mean age 65.0 +/- 0.7 years). PAD was diagnosed by measurement of the toe-brachial index (TBI). Serum osteoprotegerin was measured using ELISA. Results: The mean osteoprotegerin level was significantly higher in patients with PAD in comparison to patients without PAD (18.2 +/- 1.0 vs. 13.1 +/- 2.0 pmol/L, p = 0.014). Significant univariate correlations between TBI and osteoprotegerin level (r = - 0.308; p < 0.001), age, body mass index, and HDL cholesterol were observed. In the multivariate linear regression analysis, serum osteoprotegerin (beta = - 0.005; p = 0.020), higher age, and male gender were signifi cant predictors of TBI. When 25(OH) vitamin D was introduced into the mentioned model, OPG was no longer a signifi cant predictor of TBI and was replaced in the model with vitamin D (beta = 0.009, p = 0.001). This finding suggests a role of OPG as a mediator of the effects of 25(OH)vitamin D. Conclusions: Serum osteoprotegerin level is significantly associated with both the presence and severity of PAD in patients with T2D. Osteoprotegerin might be a biomarker for the presence of atherosclerotic disease in patients with T2DM.